Helix BioMedix, Inc. (HXBM)

OTCMKTS · Delayed Price · Currency is USD

6.45

-0.73 (-10.17%)

At close: Jun 10, 2025

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY TTM	FY NaN	FY NaN	FY NaN	FY NaN	NaN - NaN
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010	Dec '09 Dec 31, 2009	NaN - NaN
Licensing Fees	997.73K	Log In	Log In	Log In	Log In	Upgrade
Licensing Fees Growth	-42.66%	Log In	Log In	Log In	Log In	Upgrade
Peptide and Consumer Product	-	Log In	Log In	Log In	Log In	Upgrade
License Fee and Peptide Sales	-	Log In	Log In	Log In	Log In	Upgrade
License Fee and Peptide Sales Growth	-	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY TTM	FY NaN	FY NaN	FY NaN	FY NaN	NaN - NaN
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010	Dec '09 Dec 31, 2009	NaN - NaN
United States	997.73K	Log In	Log In	Log In	Log In	Upgrade
United States Growth	-43.14%	Log In	Log In	Log In	Log In	Upgrade